Designing Transformative Clinical Trials in the Cancer Genome Era

Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials

(2012) D. A. Berry et al.   CLINICAL CANCER RESEARCH

Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit

(2012) Marie-Cécile Le Deley et al.   Clinical Trials

Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial

(2012) Ben Tran et al.   INTERNATIONAL JOURNAL OF CANCER

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

(2012) Laura J. Esserman et al.   JOURNAL OF CLINICAL ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Molecular prescreening to select patient population in early clinical trials

(2012) Jordi Rodón et al.   Nature Reviews Clinical Oncology

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

(2012) B. Sen et al.   Science Translational Medicine

Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer

(2011) Jacqueline A. Hall et al.   BIOPRESERVATION AND BIOBANKING

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

(2011) Yasushi Yatabe et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-small-cell lung cancer

(2011) Peter Goldstraw et al.   LANCET

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance

(2010) B. I. Rini   CLINICAL CANCER RESEARCH

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

(2010) J. E. Dancey et al.   CLINICAL CANCER RESEARCH

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif

(2009) Sonia Moretti et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Clinical Trial Designs for Targeted Agents

(2008) A. Hoering et al.   CLINICAL CANCER RESEARCH

Cancer: The Road to Amiens

(2008) David J. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY